Galderma Joins Swiss Market Index in Fast Track to Blue-Chip Status
Event summary
- Galderma (SIX: GALD) begins trading in the Swiss Market Index (SMI) on September 21, 2026, just three years after its IPO.
- Net sales grew from $4.41 billion in 2024 to $5.207 billion in 2025, with H1 2026 showing 24.6% YoY growth at constant currency.
- Full-year 2026 net sales guidance raised to 19-21% growth from 17-20%, with Core EBITDA margin guidance reaffirmed at ~26%.
- L'Oréal Group holds 20% of Galderma shares, with 80% in free float.
The big picture
Galderma's SMI inclusion underscores its rapid ascent as a pure-play dermatology leader, capitalizing on a fragmented market with high-growth potential. The company's disciplined execution across aesthetics, skincare, and therapeutics positions it to challenge incumbents like Allergan and Johnson & Johnson's dermatology divisions. With L'Oréal as a strategic anchor shareholder, Galderma's public-market trajectory will test whether niche category leadership can sustain premium valuations in volatile healthcare markets.
What we're watching
- Growth Sustainability
- Whether Galderma can maintain its 24.6% YoY growth trajectory through H2 2026 amid heightened market expectations.
- Margin Expansion
- The pace at which Galderma achieves its ~26% Core EBITDA margin target in a year of significant operational scaling.
- Investor Sentiment
- How SMI inclusion impacts institutional investor allocation to Galderma amid broader market volatility.